Metabolic Rewiring and the Characterization of Oncometabolites.
Diren Beyoğlu,Jeffrey R. Idle +1 more
TLDR
In this article, the authors defined oncometabolites in the context of the metabolic phenotype of cancer cells through metabolomics and used them to identify low-molecular weight metabolites that exist in cells and organisms.Abstract:
The study of low-molecular-weight metabolites that exist in cells and organisms is known as metabolomics and is often conducted using mass spectrometry laboratory platforms. Definition of oncometabolites in the context of the metabolic phenotype of cancer cells has been accomplished through metabolomics. Oncometabolites result from mutations in cancer cell genes or from hypoxia-driven enzyme promiscuity. As a result, normal metabolites accumulate in cancer cells to unusually high concentrations or, alternatively, unusual metabolites are produced. The typical oncometabolites fumarate, succinate, (2R)-hydroxyglutarate and (2S)-hydroxyglutarate inhibit 2-oxoglutarate-dependent dioxygenases, such as histone demethylases and HIF prolyl-4-hydroxylases, together with DNA cytosine demethylases. As a result of the cancer cell acquiring this new metabolic phenotype, major changes in gene transcription occur and the modification of the epigenetic landscape of the cell promotes proliferation and progression of cancers. Stabilization of HIF1α through inhibition of HIF prolyl-4-hydroxylases by oncometabolites such as fumarate and succinate leads to a pseudohypoxic state that promotes inflammation, angiogenesis and metastasis. Metabolomics has additionally been employed to define the metabolic phenotype of cancer cells and patient biofluids in the search for cancer biomarkers. These efforts have led to the uncovering of the putative oncometabolites sarcosine, glycine, lactate, kynurenine, methylglyoxal, hypotaurine and (2R,3S)-dihydroxybutanoate, for which further research is required.read more
Citations
More filters
Journal ArticleDOI
Microbiome and Metabolomics in Liver Cancer: Scientific Technology
TL;DR: An overview of liver metabolomics is provided in this article , with a focus on currently available technologies and how they have been used in clinical and translational research, followed by pathway processing in liver cancer.
Journal ArticleDOI
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
Alessandro Barbato,Cesarina Giallongo,Sebastiano Giallongo,Alessandra Romano,Grazia Scandura,Saoca Concetta,T. Zuppelli,Marco Lolicato,Giacomo Lazzarino,Nunziatina Laura Parrinello,Vittorio Del Fabro,Paolo Fontana,M. Aguennoz,Giovanni Li Volti,Giuseppe A. Palumbo,Francesco Di Raimondo,Daniele Tibullo +16 more
TL;DR: In this paper , the impact of high lactate concentration on metabolism of malignant plasma cells (PCs) and its impact on the efficacy of proteasome inhibitors (PIs) was explored by colorimetric assay on MM patient's sera.
Journal ArticleDOI
Unconventional roles of lactate along the tumor and immune landscape
TL;DR: Lactate has been recognized as a multifunctional molecule orchestrating many aspects of the disease onset and progression as discussed by the authors , and the main recent findings from the EMBO workshop on Lactate: Unconventional Roles of a Nutrient Along the Tumor Landscape.
Journal ArticleDOI
Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma.
Mario Cioce,Claudia Canino,Harvey I. Pass,Giovanni Blandino,Sabrina Strano,Vito Michele Fazio,Vito Michele Fazio,Vito Michele Fazio +7 more
TL;DR: In this paper, an early mediator of the adaptive response to pem in chemoresistant mesothelioma and, possibly, other malignancies has been found.
Journal ArticleDOI
Cytidine deaminase deficiency in tumor cells is associated with sensitivity to a naphthol derivative and a decrease in oncometabolite levels
Hamza Mameri,Géraldine Buhagiar-Labarchède,Gaelle Fontaine,Céline Corcelle,Caroline Barette,Rosine Onclercq-Delic,Claire Beauvineau,Florence Mahuteau-Betzer,Mounira Amor-Guéret +8 more
TL;DR: In this paper , a naphthol derivative, X55, targeting CDA-deficient tumor cells preferentially, without affecting the growth of non-tumoral cells regardless of CDA expression status.
References
More filters
Journal ArticleDOI
Hallmarks of cancer: the next generation.
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
TL;DR: It is proposed that the metabolism of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass needed to produce a new cell.
Journal ArticleDOI
Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid
James D. Watson,Francis Crick +1 more
TL;DR: The determination in 1953 of the structure of deoxyribonucleic acid (DNA), with its two entwined helices and paired organic bases, was a tour de force in X-ray crystallography and opened the way for a deeper understanding of perhaps the most important biological process.
Journal ArticleDOI
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Williams Parsons,Siân Jones,Xiaosong Zhang,Jimmy Lin,Rebecca J. Leary,Philipp Angenendt,Parminder Mankoo,Hannah Carter,I-Mei Siu,Gary L. Gallia,Alessandro Olivi,Roger E. McLendon,B.K. Ahmed Rasheed,Stephen T. Keir,Tatiana Nikolskaya,Yuri Nikolsky,Dana A. Busam,Hanna Tekleab,Luis A. Diaz,James Hartigan,Doug R. Smith,Robert L. Strausberg,Suely Kazue Nagahashi Marie,Sueli Mieko Oba Shinjo,Hai Yan,Gregory J. Riggins,Darell D. Bigner,Rachel Karchin,Nick Papadopoulos,Giovanni Parmigiani,Bert Vogelstein,Victor E. Velculescu,Kenneth W. Kinzler +32 more
TL;DR: Recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival.